Recent Updates
Recently added Catalysts

PF-08098488

Phase 1

Pancreatic Ductal Adenocarcinoma | Small molecule | Oncology |Pfizer, Inc.|Trials Updated: Oct 29, 2026

PF-08098488 development status

Highest phase Phase 1
Registered trials 1 across 1 sponsor since Oct 2026

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

CONTROLLED
Total Trials1
Total Enrollment280

FDA Designations

No designations recorded

PF-08098488 clinical trials

PF-08098488 · 1 trial · 5 indications

Phase 1 1
NCT07903415A Study to Learn About the Study Medicine Called PF-08098488 in People With Advanced Solid Tumors.Pancreatic Ductal Adenocarcinoma
RECRUITING280 Analytics
PHASE1RECRUITING
A Study to Learn About the Study Medicine Called PF-08098488 in People With Advanced Solid Tumors.
Pancreatic Ductal Adenocarcinoma
NCT07903415280
Unlock trial analytics

Study Endpoints

Primary Endpoints

Incidence of Adverse Events (AEs)
Start of study treatment to 30 days after the last dose of study drug administration or start of new anticancer therapy (whichever occurs first)

Number of participants with AEs, characterized by type, frequency, severity, seriousness, and relationship to study intervention during the AE evaluation period.

Part 1: Recommended Monotherapy Dose(s) for Expansion (RDEM)
From first dose through completion of Part 1, an average of 1 year
Part 2: Recommended Monotherapy Dose for Further Development
From first dose through completion of Part 2, an average of 2 years

Secondary Endpoints

Objective Response Rate (ORR)
From baseline until first documented disease progression, death, or start of new anticancer therapy, whichever occurs first, up to approximately 3 years
Duration of Response (DOR)
From the date of first objective response until disease progression or death due to any cause, whichever occurs first, up to approximately 3 years
Progression Free Survival (PFS)
From first dose until disease progression or death due to any cause, whichever occurs first, up to approximately 3 years
Unlock Study Endpoints

Study Design & Arms

AllocationNON_RANDOMIZED
MaskingNONE
ModelSEQUENTIAL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Part 1 Dose EscalationEXPERIMENTALDifferent groups of participants will receive different doses and/or schedules of the study drug
Part 2 Dose ExpansionEXPERIMENTALParticipants in tumor-specific groups will receive 1 dosing regimen deemed to be safe in Part 1
Part 2 Dose OptimizationEXPERIMENTALParticipants will be assigned to one of two dosing regimens deemed to be safe in Part 1

Interventions

NameTypeDescription
PF-08098488DRUGIV infusion
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites2

Inclusion Criteria: * 18 years of age or older * Advanced non-small cell lung cancer, pancreatic ductal adenocarcinoma, gastric cancer (including gastroesophageal junction carcinoma), or esophageal cancer. * Eastern Cooperative Oncology Group (ECOG) Performance status 0-1 * Measurable disease * Mus...

Countries:United States
Unlock Eligibility Criteria

Recent Changes (Last 90 Days)

LOWOct 29, 2026NCT07903415NEW_TRIAL: changed
LOWOct 29, 2026NCT07903415NEW_TRIAL: changed

Explore more on BiopharmaWatch

Pfizer, Inc. (PFE)Pipeline, catalysts, financials, insiders and newsPancreatic Ductal Adenocarcinoma disease mapEvery company developing for Pancreatic Ductal Adenocarcinoma, by stage and capitalFDA calendarUpcoming PDUFA dates, AdComs and approval oddsPDUFA calendarEvery scheduled FDA decision date, month by monthHistorical FDA calendarPast decisions and how the stock moved on eachCatalyst SyncUpcoming readouts and decisions, screened by runway and phaseBiotech stock screenerFilter by clinical phase, cash runway and market capDrugs A to ZEvery drug page starting with PCompanies A to ZEvery biotech and pharma company we track